Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: Marei, Hany E.S.; Lashen, Samah; Farag, Amany; Althani, Asmaa; Afifi, Nahla; A, Abd‐Elmaksoud; Rezk, Shaymaa; Pallini, Roberto; Casalbore, Patrizia; Cenciarelli, Carlo
• Is Part Of: Journal of cellular physiology. Volume 230:Issue 7(2015:Jul.)
• Page Start: 1614
• Page End: 1629
• Publication Date: 2015-07
• Subjects: Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.24909
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract : Parkinson's disease (PD) is a neurological disorder characterized by the loss of midbrain dopaminergic (DA) neurons. Neural stem cells (NSCs) are multipotent stem cells that are capable of differentiating into different neuronal and glial elements. The production of DA neurons from NSCs could potentially alleviate behavioral deficits in Parkinsonian patients; timely intervention with NSCs might provide a therapeutic strategy for PD. We have isolated and generated highly enriched cultures of neural stem/progenitor cells from the human olfactory bulb (OB). If NSCs can be obtained from OB, it would alleviate ethical concerns associated with the use of embryonic tissue, and provide an easily accessible cell source that would preclude the need for invasive brain surgery. Following isolation and culture, olfactory bulb neural stem cells (OBNSCs) were genetically engineered to express hNGF and GFP. The hNFG‐GFP‐OBNSCs were transplanted into the striatum of 6‐hydroxydopamin (6‐OHDA) Parkinsonian rats. The grafted cells survived in the lesion environment for more than eight weeks after implantation with no tumor formation. The grafted cells differentiated in vivo into oligodendrocyte‐like (25 ± 2.88%), neuron‐like (52.63 ± 4.16%), and astrocyte ‐like (22.36 ± 1.56%) lineages, which we differentiated based on morphological and immunohistochemical criteria. Transplanted rats exhibited a significant partial correction in stepping and placing in non‐pharmacological behavioral tests, pole and rotarod tests. Taken together, our data encourage further investigations of the possible use of OBNSCs as a promising cell‐based therapeutic strategy for Parkinson's disease. J. Cell. Physiol. 230: 1614–1629, 2015. © 2014 Wiley Periodicals, Inc., A Wiley Company